⚡ Asset Showdown Engine

LLY vs NVO

Head-to-head financial comparison for Eli Lilly and Co (LLY) and Novo Nordisk A/S (NVO).

🏆 Showdown Verdict

LLY leads NVO in 9 of 17 key financial metrics.

LLY: 9 wins · NVO: 8 wins
NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals

LLY

Eli Lilly and Co
$1,270.89
-1.09%
After hours
52-Week Range 92.1% of High
Low: $793.82 High: $1,311.75
💼
Profitability Winner Higher Operating & Net Margins
🚀
Performance Winner Higher Historical Returns
🏛️
Scale Leader Larger Market Cap
OMX NORDIC EXCHANGE COPENHAGEN A/S · Pharmaceuticals

NVO

Novo Nordisk A/S
$1,270.89
-1.09%
🌆 After hours
🌆 After-Hours: $1,273.38 (+0.21%)
52-Week Range 92.1% of High
Low: $793.82 High: $1,311.75
💼
Profitability Winner Higher Operating & Net Margins
🚀
Performance Winner Higher Historical Returns
🏛️
Scale Leader Larger Market Cap
OMX NORDIC EXCHANGE COPENHAGEN A/S · Pharmaceuticals

NVO

Novo Nordisk A/S
$39.06
-0.71%
🌆 After hours
🌆 After-Hours: $39.10 (+0.10%)
52-Week Range 13.6% of High
Low: $35.12 High: $64.16
🏷️
Valuation Winner Lower P/E & Multiples
💰
Income Winner Higher Dividend Yield

Normalized % Return Comparison

Both assets indexed to 0.0% at the period start: ((Price_t - Price_0) / Price_0 * 100)

Benchmark:
LLY (Eli Lilly and Co) +56.14%
NVO (Novo Nordisk A/S) -27.97%
LLY leads by +84.11%
-49.8%-19.4%+11.1%+41.5%+71.9% Oct '25Jan '26Apr '26Jul '26Oct '26

Metric-by-Metric Breakdown

Direct quantitative comparison across valuation, margins, growth, and returns.

Financial Metric LLY NVO Showdown Advantage
Valuation & Multiples
Price Current market price per share / unit $1,270.89 $39.06 —
Market Capitalization Total aggregate market value of equity $1.20T $1.16T 👑 LLY Larger
P/E Ratio (Trailing TTM) Price-to-earnings multiple (lower positive is cheaper) 44.83x 9.76x 👑 NVO Cheaper
Forward P/E Price-to-projected next year earnings multiple 26.25x 11.50x 👑 NVO Lower
PEG Ratio P/E divided by earnings growth rate (<1.0 considered undervalued) 1.34 — 👑 LLY Lower
Price to Sales (P/S) Price relative to trailing revenue 15.03x 3.45x 👑 NVO Lower
Price to Book (P/B) Stock price relative to book equity per share 33.34x 4.82x 👑 NVO Lower
Profitability & Margins
Gross Profit Margin Gross revenue retained after cost of goods sold 83.40% 80.65% 👑 LLY Higher
Operating Margin Operating income generated per dollar of revenue 42.22% 43.13% 👑 NVO Higher
Net Profit Margin Net bottom-line profit generated per dollar of revenue 33.53% 35.35% 👑 NVO Higher
Return on Equity (ROE) Net income earned per dollar of shareholders' equity 92.58% 59.09% 👑 LLY Higher
Historical Performance & Growth
Revenue Growth (YoY) Year-over-year top-line revenue expansion rate +47.67% +2.12% 👑 LLY Higher
1-Month % Return Historical total price return over the past 30 days +11.63% -6.39% 👑 LLY Higher
6-Month % Return Historical total price return over the past 180 days +33.44% +5.23% 👑 LLY Higher
1-Year % Return Historical total price return over the past 52 weeks +56.14% -27.97% 👑 LLY Higher
5-Year % Return Historical total price return over 5 years +445.73% +2296.32% 👑 NVO Higher
Dividends & Risk
Dividend Yield Annual dividend distributions relative to current price 0.75% 1.00% 👑 NVO Higher
Beta (Volatility vs S&P 500) Market sensitivity (1.0 = equal to market, <1.0 = lower volatility) 0.42 1.95 —
52-Week High & Low Extreme trading boundaries over trailing year $793.82 – $1,311.75 $35.12 – $64.16 —